M&A

M&A

Lincoln Pharma acquires Cephalosporin plant in Gujarat's Mehsana

BSE Disclosure  

Publicly-listed drug maker Lincoln Pharmaceuticals Ltd has acquired a facility in Mehsana, Gujarat for making Cephalosporin products, and expects the commercial operations from the plant to start from March 2022. It has earmarked INR 30 crore for expansion of its Cephalosporin products portfolio. The plant will cater to all the Cephalosporin products such as tablet, capsule, dry syrup and injectables. The entire expansion for Cephalosporin products will be funded from internal accruals. Lincoln is in the process of applying for WHO GMP certifications for the Mehsana facility and expects to receive them by December 2021. It is planning to manufacture 20 plus Cephalosporin products and is planning to start product registration soon for the domestic as well as overseas markets.